Online inquiry

IVTScrip™ mRNA-Anti-IL17A, AG1-25(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1844MR)

This product GTTS-WQ1844MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IL17A gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens; Chimeric
RefSeq NM_002190.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3605
UniProt ID Q16552
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL17A, AG1-25(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ1844MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2965MR IVTScrip™ mRNA-Anti-IL33, ANB020(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ANB020
GTTS-WQ6891MR IVTScrip™ mRNA-Anti-CX3CL1, E-6011(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA E-6011
GTTS-WQ6786MR IVTScrip™ mRNA-Anti-ERBB2, DS-8201(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA DS-8201
GTTS-WQ13005MR IVTScrip™ mRNA-Anti-CSF3R, PEG-G-CSF(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PEG-G-CSF
GTTS-WQ12612MR IVTScrip™ mRNA-Anti-ERBB2, OMNITARG™(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA OMNITARG™
GTTS-WQ14838MR IVTScrip™ mRNA-Anti-CD70, SGN-75(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA SGN-75
GTTS-WQ15372MR IVTScrip™ mRNA-Anti-CD37, TRU-016(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA TRU-016
GTTS-WQ1376MR IVTScrip™ mRNA-Anti-IL12B, ABT-874(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABT-874
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW